Loading...

Cann Group Limited

CAN.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
A$0.01
A$-0.00(-6.67%)

Cann Group Limited (CAN.AX) Stock Competitors & Peer Comparison

See (CAN.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CAN.AXA$0.01-6.67%9.8M-0.15-A$0.10N/A
CAU.AXA$0.54+0.00%300.5M-16.88-A$0.03N/A
AFP.AXA$2.40+0.00%251.7M24.00A$0.10+0.43%
PBP.AXA$2.98-0.33%242.3M29.80A$0.10N/A
LV1.AXA$0.92+0.00%144.1M3.05A$0.30N/A
VLS.AXA$2.21-2.21%122.8M14.12A$0.16+4.42%
IHL.AXA$0.04-10.87%65.1M-0.03-A$1.30N/A
MVP.AXA$0.65+16.22%64.2M-1.68-A$0.34N/A
ANP.AXA$0.06-4.92%52.3M-2.90-A$0.02N/A
VIT.AXA$0.07-1.37%47M7.10A$0.01N/A
Showing 1 to 10 of 29 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CAN.AX vs CAU.AX Comparison August 2025

CAN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CAN.AX stands at 9.8M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, CAN.AX is priced at A$0.01, while CAU.AX trades at A$0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CAN.AX currently has a P/E ratio of -0.15, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, CAN.AX's ROE is -4.70%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, CAN.AX is more volatile compared to CAU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CAN.AX.Check CAU.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;